acute coronary syndrome - antithrombotics - patients with a recent ACS clinical trials results meta-analysis

<h1> <a href="TM16-8-antithrombotics-acute coronary syndrome" > <strong>acute coronary syndrome</strong> - antithrombotics </a> - patients with a recent ACS trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t8586.htm"> APPRAISE-1 (10mg od), 2009 </a> <br> NCT00313300 </td> <td> apixaban 10 mg once daily<br>  <i>versus</i> <br> placebo </td> <td> patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) </td> <td> follow-up 6 months<br> n=318/611<br> Parallel groups<br> double blind <br> Europe, Middle East, North America </td> </tr> <tr> <td> <a href="../TRC_t8614.htm"> APPRAISE-1 (2.5 mg bid), 2009 </a> <br> NCT00313300 </td> <td> Apixaban 2.5mg twice daily <br>  <i>versus</i> <br> placebo </td> <td> patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) </td> <td> follow-up 6 months<br> n=-9/611<br> <br> double blind <br> Europe, Middle East, North America </td> </tr> <tr> <td> <a href="../TRC_t9768.htm"> ATLAS ACS-TIMI 46, 2009 </a> <br> NCT00402597 </td> <td> rivaroxaban 5 mg, 10 mg, or 20 mg once daily, 2.5 mg, 5 mg, or 10 mg twice daily<br>  <i>versus</i> <br> placebo </td> <td> recent ACS patients treated with aspirin alone (n=761) or aspirin plus clopidogrel (n=2730) </td> <td> follow-up 6 months<br> n=2331/1160<br> Parallel groups<br> double blind <br> 27 countries </td> </tr> <tr> <td> <a href="../TRC_t10003.htm"> ATLAS ACS TIMI 51, </a> <br> NCT00809965 </td> <td> rivaroxaban (2.5 mg twice daily or 5 mg twice daily) in addition to standard care<br>  <i>versus</i> <br> placebo </td> <td> patients with a recent ACS </td> <td> follow-up <br> n=16000/0<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t10337.htm"> B0661004, </a> <br> NCT00852397 </td> <td> Apixaban 2.5 or 5 mg twice daily<br>  <i>versus</i> <br> placebo </td> <td> patients with recent (<=7 Days) acute coronary syndrome </td> <td> follow-up 24 weeks<br> n=-9/-9<br> Parallel groups<br> double blind <br> japan </td> </tr> <tr> <td> <a href="../TRC_t10338.htm"> APPRAISE 2 (CV185-068), </a> <br> NCT00831441 </td> <td> apixaban 5mg twice daily<br>  <i>versus</i> <br> placebo </td> <td> patients with a recent acute coronary syndrome </td> <td> follow-up <br> n=10848/0<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>APPRAISE-1 (10mg od), 2009 : </b> Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. <i>Circulation 2009;:</i> [PMID 19470889] </p> <p> <b>APPRAISE-1 (2.5 mg bid), 2009 : </b> <i>Circulation 2009;:</i> [PMID 19470889] </p> <p> <b>ATLAS ACS-TIMI 46, 2009 : </b> Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CMRivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. <i>Lancet 2009 Jul 4;374:29-38</i> [PMID 19539361] </p>